These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38718473)

  • 1. AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B.
    Sarangi P; Kumar N; Sambasivan R; Ramalingam S; Amit S; Chandra D; Jayandharan GR
    Thromb Res; 2024 Jun; 238():151-160. PubMed ID: 38718473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.
    Ohmori T; Nagao Y; Mizukami H; Sakata A; Muramatsu SI; Ozawa K; Tominaga SI; Hanazono Y; Nishimura S; Nureki O; Sakata Y
    Sci Rep; 2017 Jun; 7(1):4159. PubMed ID: 28646206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gRNA Vector Level Determines the Outcome of Systemic AAV CRISPR Therapy for Duchenne Muscular Dystrophy.
    Wasala NB; Million ED; Watkins TB; Wasala LP; Han J; Yue Y; Lu B; Chen SJ; Hakim CH; Duan D
    Hum Gene Ther; 2022 May; 33(9-10):518-528. PubMed ID: 35350865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
    Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
    Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.
    Monahan PE; Lothrop CD; Sun J; Hirsch ML; Kafri T; Kantor B; Sarkar R; Tillson DM; Elia JR; Samulski RJ
    Mol Ther; 2010 Nov; 18(11):1907-16. PubMed ID: 20700109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.
    Margaritis P; Roy E; Faella A; Downey HD; Ivanciu L; Pavani G; Zhou S; Bunte RM; High KA
    Blood; 2011 Apr; 117(15):3974-82. PubMed ID: 21325603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances in AAV-CRISPR/Cas9-Mediated Hemophilia A Gene Therapy --Review].
    Fang S; Wang G; Yang LH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1890-1893. PubMed ID: 38071078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational Engineering and Preclinical Evaluation of Neddylation and SUMOylation Site Modified Adeno-Associated Virus Vectors in Murine Models of Hemophilia B and Leber Congenital Amaurosis.
    Maurya S; Mary B; Jayandharan GR
    Hum Gene Ther; 2019 Dec; 30(12):1461-1476. PubMed ID: 31642343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High levels of AAV vector integration into CRISPR-induced DNA breaks.
    Hanlon KS; Kleinstiver BP; Garcia SP; Zaborowski MP; Volak A; Spirig SE; Muller A; Sousa AA; Tsai SQ; Bengtsson NE; Lööv C; Ingelsson M; Chamberlain JS; Corey DP; Aryee MJ; Joung JK; Breakefield XO; Maguire CA; György B
    Nat Commun; 2019 Sep; 10(1):4439. PubMed ID: 31570731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice.
    Wang L; Yang Y; Breton CA; White J; Zhang J; Che Y; Saveliev A; McMenamin D; He Z; Latshaw C; Li M; Wilson JM
    Blood; 2019 Jun; 133(26):2745-2752. PubMed ID: 30975639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
    El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
    Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII.
    Chen H; Shi M; Gilam A; Zheng Q; Zhang Y; Afrikanova I; Li J; Gluzman Z; Jiang R; Kong LJ; Chen-Tsai RY
    Sci Rep; 2019 Nov; 9(1):16838. PubMed ID: 31727959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation.
    Moreno AM; Fu X; Zhu J; Katrekar D; Shih YV; Marlett J; Cabotaje J; Tat J; Naughton J; Lisowski L; Varghese S; Zhang K; Mali P
    Mol Ther; 2018 Jul; 26(7):1818-1827. PubMed ID: 29754775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia.
    Pan X; Philippen L; Lahiri SK; Lee C; Park SH; Word TA; Li N; Jarrett KE; Gupta R; Reynolds JO; Lin J; Bao G; Lagor WR; Wehrens XHT
    Circ Res; 2018 Sep; 123(8):953-963. PubMed ID: 30355031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox.
    Senís E; Fatouros C; Große S; Wiedtke E; Niopek D; Mueller AK; Börner K; Grimm D
    Biotechnol J; 2014 Nov; 9(11):1402-12. PubMed ID: 25186301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divergent susceptibilities to AAV-SaCas9-gRNA vector-mediated genome-editing in a single-cell-derived cell population.
    Morsy SG; Tonne JM; Zhu Y; Lu B; Budzik K; Krempski JW; Ali SA; El-Feky MA; Ikeda Y
    BMC Res Notes; 2017 Dec; 10(1):720. PubMed ID: 29221488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.
    Yin C; Zhang T; Qu X; Zhang Y; Putatunda R; Xiao X; Li F; Xiao W; Zhao H; Dai S; Qin X; Mo X; Young WB; Khalili K; Hu W
    Mol Ther; 2017 May; 25(5):1168-1186. PubMed ID: 28366764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.